All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Topical oestrogens should be used in the smallest effective amount for the shortest duration to minimise systemic effects. Treatment should be evaluated after 12 weeks.
The BNF states that the risk of endometrial hyperplasia and carcinoma is increased when systemic oestrogens are administered alone for prolonged periods. The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.
Information on the safety of the following products can be found in the individual manufacturer's Summary of Product Characteristics, which state:
Most women will be able to comply with vaginal cream and this should be first choice.
These preparations may damage latex condoms and diaphragms – refer to individual manufacturer's Summary of Product Characteristics.
Formulary guidance on the management of menopause can be accessed here.
Indications and dose
Notes
Indications
Dose
Notes
Indications and dose
Notes
The routine commissioning of ospemifene (Senshio) is not accepted in Devon for the treatment of vulvar and vaginal atrophy (see Commissioning Policy for more information).
The routine commissioning of prasterone (Intrarosa) is not accepted in Devon for the treatment of vulvar and vaginal atrophy (see Commissioning Policy for more information).
Indications
Dose
Notes